Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS - RICH TV LIVE
Channel: RICH TV LIVE
Date: 30/03/2022

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS - RICH TV LIVE - March 30, 2022 - #numinuswellness #maps #richtvlive #business #news #finance #education #psychedelics #therapy #medicine #mdma #ptsd #richtv #trading 

 Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has advanced to the next implementation phase in the clinical trial "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)" sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by MAPS Public Benefit Corporation (MAPS PBC), by enrolling and dosing the first clinical trial volunteer in Canada 

Numinus hosts the Canadian sites for MAPPUSX, through two purpose-designed clinics located in Montreal and Vancouver . This week, the Montreal site began drug administration, led by trial co-therapists Dr. Joe Flanders , VP Psychology, Numinus, and Dr. Emma Hapke , Staff Psychiatrist, University Health Network and Principal Investigator for the MAPS-sponsored trial. The treatment follows MAPS' protocol of three sessions of MDMA administration and therapy, each to be followed by three integration sessions. The full program is expected to complete in mid-summer 2022.

"Numinus is excited to administer the first MDMA-assisted therapy dosing of MDMA at our clinics and contribute to the growing body of MAPS' research," says Dr. Flanders. "Designed with accessibility and ethics at its core, we look forward to the continuation of this study and translating the findings into clinical practice."

MAPPUSX is an extension of MAPS' Phase 3 studies to investigate the safety and efficacy of MDMA-assisted therapy for treating severe PTSD. The MAPPUSX trial is open to those participants from the Phase 3 studies who received the placebo drug and therapy and those who could not receive treatment due to COVID restrictions. The resulting safety data will be provided to regulatory bodies in the sponsor's New Drug Application.

"We are proud of our clinical and research teams who have been and continue to be instrumental in driving MDMA-assisted therapy for PTSD research forward in Canada ," said Payton Nyquvest , CEO and founder, Numinus. "This week's trial progress is another step in our strengthening collaboration with MAPS as we work together to make psychedelic-assisted therapy accessible to those in need. We will continue to work with MAPS, Health Canada and the industry to help make MDMA-assisted therapy a reality."

JOIN RICH TV LIVE TRADING CLUB HERE -  http://www.richtv.io 

Subscribe - https://www.youtube.com/c/RICHTVLIVE
Visit - http://richtv.io/ a community for stocks, cryptocurrency, news, and trending topics. #richtvlive #RICHTV.IO #richpicksdaily #stocks #business #news #finance #education #entertainment #money #defi #nft #metaverse #trading #stockmarket

Popular Uploads - https://goo.gl/tbvXGg
Most Recent Upload - https://goo.gl/unKXBy
YouTube Channel Page - https://goo.gl/yUdG7w
Subscribe - http://www.youtube.com/c/RICHTVLIVE
Rich TV Live Playlist - https://goo.gl/e116JF
RICH TV LIVE TOP 10 STOCKS Playlist - https://www.youtube.com/playlist?list=PLiBGEhbXkQPCfeYmBKHyXXu8dZc3YkkbW&disable_polymer=true

Disclaimer

RICH TV LIVE INC. company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. RICH TV LIVE INC. sponsored $1500 CAD for digital video services.

Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. 

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators.ca/.